Comparer des méthodes

	Analyse adaptative dose-réponse	Essai clinique randomisé adaptatif
Domaine	Épidémiologie	Épidémiologie
Famille	Process / pipeline	Process / pipeline
Année d'origine	2000s (key papers 2005–2007; ICH E4 guidance 1994 for classical dose-response)	Late 1990s–2000s (widespread adoption post-2010)
Auteur d'origine	Frank Bretz, José Pinheiro and colleagues; foundational MCP-Mod framework	Donald Berry and colleagues; formalized by FDA guidance in 2010 and 2019
Type	Adaptive statistical design and analysis	Experimental clinical trial design
Source fondatrice	Bretz, F., Pinheiro, J. C., & Branson, M. (2005). Combining multiple comparisons and modeling techniques in dose-response studies. Biometrics, 61(3), 738-748.	Berry, D. A. (2006). Bayesian clinical trials. Nature Reviews Drug Discovery, 5(1), 27–36.
Alias	adaptive DRA, adaptive dose-finding analysis, adaptive exposure-response analysis, adaptive D-R modeling	adaptive RCT, adaptive trial design, response-adaptive randomization trial, adaptive clinical trial
Apparentées	6	6
Résumé	Adaptive dose-response analysis combines pre-specified dose-response modeling with planned interim looks that allow modifications — such as dropping ineffective doses or reallocating sample size — while maintaining statistical integrity. The most widely cited framework is MCP-Mod (Multiple Comparisons and Modeling), endorsed by the EMA and FDA as a fit-for-purpose methodology for dose-finding studies in drug development.	An adaptive randomized clinical trial (adaptive RCT) is a prospective experimental study that uses pre-specified rules to modify one or more trial aspects — such as sample size, allocation ratios, or treatment arms — based on accumulating data collected during the trial itself, while maintaining statistical validity and integrity of the study.